Carbapenem Antibiotics: Indications, Dosing, and Renal Adjustments
Standard Dosing Regimens
For carbapenem-resistant Enterobacterales (CRE) infections, imipenem/cilastatin/relebactam should be dosed at 1.25 g IV every 6 hours, meropenem at 1 g IV every 8 hours (extended infusion over 3 hours if MIC ≥8 mg/L), and ertapenem at 1 g IV daily for susceptible organisms. 1
Imipenem/Cilastatin Dosing
- Standard dose: 0.5-1 g IV every 6-8 hours in patients with normal renal function 2
- Severe infections: Up to 4 g/day in divided doses 3
- With relebactam (for CRE): 1.25 g IV every 6 hours 1
Meropenem Dosing
- Standard dose: 1 g IV every 8 hours 4, 2
- Maximum dose: Up to 6 g/day can be safely administered 2
- For CRE with elevated MIC: 1 g IV every 8 hours by extended infusion (3 hours) when MIC ≥8 mg/L 1
- Complicated skin/intra-abdominal infections: 1 g IV every 8 hours 4
- Meningitis (pediatric): 40 mg/kg every 8 hours 4
Ertapenem Dosing
- Standard dose: 1 g IV once daily 5
- Approved indications: Complicated intra-abdominal infections, complicated skin/skin structure infections, community-acquired pneumonia, acute pelvic infections, complicated UTIs 5
- Key distinction: Ertapenem lacks reliable Pseudomonas coverage, unlike imipenem and meropenem 2
Renal Dose Adjustments
Imipenem/Cilastatin
Dose reductions are mandatory for renal impairment to prevent seizures, which occur primarily with excessive dosing in patients with impaired renal function. 3
- CrCl 31-70 mL/min: 500 mg every 6-8 hours
- CrCl 21-30 mL/min: 500 mg every 12 hours
- CrCl 6-20 mL/min: 250-500 mg every 12 hours
- Hemodialysis: Approximately 50% removed by IHD; administer after dialysis 6
Meropenem
The half-life extends from ~1 hour in healthy patients to 13.7 hours in anuric patients 6.
- CrCl 26-50 mL/min: Standard dose every 12 hours
- CrCl 10-25 mL/min: Half dose every 12 hours
- CrCl <10 mL/min: Half dose every 24 hours
- Hemodialysis: 50% eliminated by IHD; dose after dialysis 6
- CVVHF: 25-50% eliminated 6
- CVVHDF: 13-53% eliminated 6
Ertapenem
Dose reductions are indicated only for advanced renal insufficiency; no adjustments needed for age, gender, weight, or liver disease. 5
- CrCl ≥30 mL/min: 1 g IV daily (no adjustment)
- CrCl <30 mL/min: 500 mg IV daily
- Intermittent hemodialysis: 500 mg IV daily, given after dialysis on dialysis days 7
- CVVH: 1 g IV daily 7
Critical caveat: The commonly used ertapenem doses in RRT patients may pose higher seizure risk (2.5% incidence observed), though clinical efficacy remains acceptable 7.
Clinical Indications by Infection Type
Bloodstream Infections
Duration: 7-14 days 1
For CRE bloodstream infections, newer beta-lactam/beta-lactamase inhibitor combinations are preferred over traditional carbapenems when available 1. However, for ertapenem-only-resistant Enterobacterales (EORE) that remain meropenem-susceptible, meropenem-based therapy achieves similar outcomes to anti-CRE agents and is appropriate first-line therapy 8.
Complicated Urinary Tract Infections
Duration: 5-7 days 1
All three carbapenems are effective. Ertapenem is particularly suitable given once-daily dosing and adequate urinary concentrations 5.
Complicated Intra-Abdominal Infections
Duration: 5-7 days 1
- Imipenem/cilastatin/relebactam: 1.25 g IV every 6 hours
- Meropenem: 1 g IV every 8 hours
- Ertapenem: 1 g IV daily
Hospital-Acquired/Ventilator-Associated Pneumonia
Duration: 10-14 days 1
For patients with augmented renal clearance (CrCl ≥250 mL/min), imipenem/cilastatin/relebactam at full dose (1.25 g every 6 hours) achieved 91.7% clinical response versus 44.4% with comparators, demonstrating the importance of maintaining full dosing in this population. 9
Key Clinical Considerations
Comparative Activity
- Imipenem: Slightly superior gram-positive activity 2
- Meropenem: Slightly superior gram-negative activity, including Pseudomonas 2
- Ertapenem: No reliable Pseudomonas coverage; once-daily dosing advantage 2, 5
Seizure Risk Management
Seizures are the most concerning adverse effect, occurring primarily with:
- Imipenem in patients with renal impairment or CNS pathology 3
- Excessive dosing without appropriate renal adjustment 3
- Meropenem has lower seizure risk than imipenem 2
- Ertapenem in RRT patients may have 2.5% seizure incidence 7
Mitigation strategy: Strict adherence to renal dosing schedules, particularly in patients with predisposition to seizures or receiving anticonvulsants 10.
Drug Interactions
Avoid concomitant valproic acid with carbapenems—this combination causes breakthrough seizures due to reduced valproic acid levels. 4
Probenecid increases carbapenem levels by competing for renal tubular secretion; avoid combination 4.
Resistance Considerations
For serious Pseudomonas infections, combine carbapenems with an aminoglycoside to prevent emergence of resistance during therapy, as isolates may rapidly acquire resistance when carbapenems are used alone 10.
The 2022 ESCMID guidelines found no significant mortality advantage for carbapenems over carbapenem-sparing regimens (beta-lactam/beta-lactamase inhibitors, quinolones, aminoglycosides) for third-generation cephalosporin-resistant Enterobacterales bloodstream infections, though evidence certainty was low to very low 11. This supports judicious carbapenem use to preserve their efficacy.
Augmented Renal Clearance
Do not reduce doses in patients with augmented renal clearance (CrCl ≥90 mL/min); maintain full dosing to achieve adequate drug exposures and optimal clinical outcomes. 9 Probability of target attainment exceeds 98% for susceptible pathogens (MIC ≤2 mg/L) with standard dosing 9.